![]() Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. See which 3 stocks are most likely to make moves following their insider activities. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. This means that over the past quarter there has been an increase of insiders buying their shares of INBX in relation to earlier this year. In comparison, last year the company earned a revenue of $2.51 million and had a GAAP net loss of $20.58 millionīased on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. See the top stocks recommended by analysts >īased on Inhibrxs latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $278 thousand and a GAAP net loss of $35.33 million. In a report released on November 8, Credit Suisse also maintained a Buy rating on the stock with a $46.00 price target. According to TipRanks, Benjamin has an average return of -9.0% and a 34.43% success rate on recommended stocks.Ĭurrently, the analyst consensus on Inhibrx is a Strong Buy with an average price target of $49.40, representing a 51.12% upside. ![]() The companys shares closed last Friday at $32.69.īenjamin covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Allogene Therapeutics, and Spectrum Pharmaceuticals. In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Inhibrx ( INBX - Research Report), with a price target of $40.00. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |